The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smeland, E. B.
Right arrow Articles by Godal, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smeland, E. B.
Right arrow Articles by Godal, T.

The Journal of Immunology, Vol 138, Issue 10 3179-3184, Copyright © 1987 by American Association of Immunologists

ARTICLES

Activation of human B cells: alternate options for initial triggering and effects of nonmitogenic concentrations of anti-IgM antibodies on resting and activated cells

EB Smeland, K Beiske, R Ohlsson, H Holte, E Ruud, HK Blomhoff, R Jefferis and T Godal

The monoclonal antibody 1F5, which is reactive with the CD20 (Bp 35) pan-B cell antigen, was shown to activate resting human peripheral blood B cells into the middle to late G1 phase of the cell cycle. However, in contrast to F(ab')2 fragments of polyclonal anti-mu, 1F5 synergized only weakly with B cell growth factor (BCGF) for DNA synthesis in these cells. We provide evidence that the CD20 molecule and surface immunoglobulin represent two alternative activation pathways in resting B cells. We also show that anti-immunoglobulins, during co-stimulation with BCGF, may play an important role in G1 as well as for the initial cell triggering. Thus, anti-mu in nonmitogenic concentrations was shown to provoke distinct effects on 1F5-pretreated G1 cells, as monitored by increases in cellular volumes as well as in cytoplasmic Ca2+ levels. Moreover, anti-mu could increase c-myc mRNA levels in 1F5-primed cells, implying that c-myc expression can be regulated in G1 as well as during the initial G0 to G1 transition. Partially purified human BCGF neither induced G1 entry in resting peripheral blood cells nor primed the cells for DNA synthesis. The finding that BCGF did not influence c-myc mRNA levels in resting or in activated B cells suggests that its mitogenic action does not involve the c-myc function.


This article has been cited by other articles:


Home page
 BloodHome page
G. Cartron, H. Watier, J. Golay, and P. Solal-Celigny
From the bench to the bedside: ways to improve rituximab efficacy
Blood, November 1, 2004; 104(9): 2635 - 2642.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Lomo, H. K. Blomhoff, S. E. Jacobsen, S. Krajewski, J. C. Reed, and E. B. Smeland
Interleukin-13 in Combination With CD40 Ligand Potently Inhibits Apoptosis in Human B Lymphocytes: Upregulation of Bcl-xL and Mcl-1
Blood, June 15, 1997; 89(12): 4415 - 4424.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. P. Deans, L. Kalt, J. A. Ledbetter, G. L. Schieven, J. B. Bolen, and P. Johnson
Association of 75/80-kDa Phosphoproteins and the Tyrosine Kinases Lyn, Fyn, and Lck with the B Cell Molecule CD20
J. Biol. Chem., September 22, 1995; 270(38): 22632 - 22638.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1987 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1987 by The American Association of Immunologists, Inc. All rights reserved.